Key Highlights

  • GRI Bio (NASDAQ:GRI), formerly Vallon Pharmaceuticals, traded about 16.48% lower, near USD 0.7851 intraday, in early trading on Monday, October 26, 2026, and the company has not issued a release explaining the move.
  • The company announced on Monday, August 24, 2026 that it would present late-breaking Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis at the European Respiratory Society congress.
  • The shares trade below USD 1.00, the Nasdaq minimum bid price, which makes listing compliance and financing important for a clinical-stage company.
  • The company also announced a virtual 2026 annual stockholder meeting with proxy proposals, which often cover share authorisations and financing flexibility.

A Sub-Dollar Biotech Under Pressure

GRI Bio (NASDAQ:GRI), a clinical-stage biotechnology company that completed a reverse merger with Vallon Pharmaceuticals in 2023, traded about 16.48% lower, near USD 0.7851 intraday, in early trading on Monday, October 26, 2026. The company has not issued a release explaining the move. The ticker for the former Vallon name is now GRI. Its most recent clinical news came on Monday, August 24, 2026, when it said it would present late-breaking Phase 2a data for GRI-0621, an experimental therapy for idiopathic pulmonary fibrosis, a progressive scarring lung disease, at the European Respiratory Society congress. The release highlighted lung function, anti-fibrotic biomarkers and favourable tolerability.

Why Small Clinical-Stage Biotechs Move on Thin News

GRI Bio (NASDAQ:GRI) has no marketed product, so its valuation rests on trial results and on access to cash. Phase 2a studies are small and designed to test safety and early signals, which means a favourable readout does not secure later success. Biotechs trading below USD 1.00 face the Nasdaq minimum bid rule, under which a notice can follow if the closing bid stays under that level for 30 consecutive business days. The company has previously regained compliance with the exchange, according to a published item, so the pattern is familiar. Annual meeting proxy proposals commonly seek approval for reverse splits or higher share authorisations, either of which can weigh on the price.

Risks and What to Watch

The first risk for GRI Bio (NASDAQ:GRI) is financing: a clinical-stage company with no revenue usually raises cash through equity offerings and warrants, which dilute holders. The second is listing compliance, because a price near USD 0.79 sits below the USD 1.00 minimum bid level and may require a reverse split. The third is clinical: GRI-0621 data from a small Phase 2a study may not be confirmed in larger trials, and the next stage needs funding. Intraday moves of this size on thin volume can reverse. Investors should watch for any filing on financing, the annual meeting results, any exchange notice and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that GRI Bio (NASDAQ:GRI) fell 16.48% in early trading on Monday, October 26, 2026 without a stated catalyst, and the move fits a sub-dollar clinical-stage biotech with financing and listing pressure. The company has not issued a release explaining the move. The next catalysts are any financing filing, the annual meeting, the Federal Reserve decision on Wednesday, October 28, 2026 and the next quarterly results. Early trial data are not guarantees of later results, and this is not investment advice.